PHERGain Studies Highlight New Approaches in Breast Cancer Treatment
MEDSIR has presented findings from the PHERGain and PHERGain-2 studies at the ESMO Breast 2026 congress, focusing on de-escalation strategies in HER2-positive early breast cancer. These studies explore the potential for some patients to avoid chemotherapy by using targeted therapies, achieving high disease-free survival rates. The research emphasizes a personalized approach to treatment, aiming to reduce toxicity and improve quality of life for patients. 
